| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
- Halneuron® Chemotherapy-Induced Neuropathic Pain ("CINP") Phase 2b study interim data readout remains on track as projected for Q4 2025 -
- Low discontinuation rate (6%) due to adverse events amongst the first 35 patients completing the trial suggests Halneuron® and placebo treatment have been generally well tolerated -
ATLANTA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced it has enrolled the first 50 patients in its ongoing Phase 2b CINP trial and remains on track to execute its planned interim analysis on approximately 100 patients who will have completed the four week trial during the fourth quarter of this year.
Posted In: DWTX
